Nafarelin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nafarelin
Nafarelin.svg
Systematic (IUPAC) name
(2R)-N-[(2R)-5-carbamimidamido-1-[(2S)-2-[(carbamoylmethyl)carbamoyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]-2-[(2R)-2-[(2R)-2-[(2R)-3-hydroxy-2-[(2S)-2-[(2S)-3-(1H-imidazol-4-yl)-2-{[(2R)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]-3-(naphthalen-2-yl)propanamido]-4-methylpentanamide
Clinical data
Trade names Synarel
AHFS/Drugs.com monograph
MedlinePlus a601082
Pregnancy cat.
  • X
Legal status
  • ℞-only
Routes Nasal spray
Pharmacokinetic data
Half-life 2.6 to 4 hours
Excretion renal
Identifiers
CAS number 76932-56-4 YesY
ATC code H01CA02
PubChem CID 25077649
DrugBank DB00666
ChemSpider 10482014 YesY
UNII 1X0094V6JV YesY
ChEMBL CHEMBL1201309 N
Chemical data
Formula C66H83N17O13 
Mol. mass 1321.6344 g/mol
 N (what is this?)  (verify)

Nafarelin is a gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary gland, it decreases pituitary secretion of the gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Nafarelin may be used in the treatment of estrogen-dependent conditions (such as endometriosis or uterine fibroids), to treat central precocious puberty, or to control ovarian stimulation in IVF.

Nafarelin acetate is marketed by Searle (now part of Pfizer) under the brand name Synarel. It is delivered via a nasal spray.

Side effects[edit]

Side effects of nafarelin are related to the low estrogen state. Side effects include hot flashes, vaginal dryness, headaches, mood changes, and decreased interest in sex. Some patients may experience acne, muscle pain, reduced breast size, and irritation of the tissue inside the nose. These side effects are reversible and should resolve after stopping the medication.[1]

References[edit]